Willow Biosciences says it has successfully developed scalable process for producing CBG with greater than 99% purity and no detectable THC
The process was developed as part of a 500-litre pilot-scale campaign with partner Albany Molecular Research
Company
Willow Biosciences Inc
TSE:WLLW
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow’s FutureGrownTM biotechnology platform allows large-scale production with sustainability at its core. Willow’s R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers. For more information, visit www.willowbio.com .
85 stories · page 5 of 5
Willow Biosciences set for Canada government funding to help advance its rare cannabinoids program
It will receive advisory services and conditional funding from the National Research Council of Canada Industrial Research Assistance Program
Willow Biosciences CEO says firm makes better-than-expected progress towards commercialization as it posts 2Q results
The company ended the quarter with strong liquidity, including around $12.2 million of cash on hand as of June 30, 2020, as it races towards production
ATB Capital says Willow Biosciences faces large commercialization opportunity with initial production run of CBG
Willow has developed a proprietary process to manufacture the cannabis compound in commercial quantities
Willow Biosciences kicks off pilot production run of high-purity CBG, a non-psychoactive cannabinoid compound
Willow will manufacture the high purity, plant-derived compounds for pharmaceutical, health and wellness and consumer packaged goods industries